9 March 2023
N4 Pharma plc
("N4 Pharma" or the "Company")
Posting of Annual Report & Notice of AGM
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that its Annual Report and Accounts for the year ended 31 December 2022 and Notice of its Annual General Meeting ("AGM") has been posted to shareholders.
The AGM will be held at 11.00 a.m. on 3 April 2023 at Shakespeare Martineau LLP, 6th Floor 60 Gracechurch Street, London, EC3V 0HR.
The Group's Annual Report and Accounts and the Notice of AGM will be made available on the Company's website: https://www.n4pharma.com/
Enquiries:
| N4 Pharma plc |
|
| Nigel Theobald, CEO | Via IFC Advisory |
| Luke Cairns, Executive Director | |
|
|
|
| SP Angel Corporate Finance LLP | Tel: +44(0)20 3470 0470 |
| Nominated Adviser and Joint Broker | |
| Matthew Johnson/Kasia Brzozowska (Corporate Finance) | |
| Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | |
|
|
|
| Turner Pope Investments (TPI) Limited | Tel: +44(0)20 3657 0050 |
| Joint Broker | |
| Andy Thacker James Pope | |
|
| |
| IFC Advisory Ltd | Tel: +44(0)20 3934 6630 |
| Financial PR | |
| Graham Herring | |
| Zach Cohen | |
|
| |
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through preclinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.